



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John F. Braganza, et al.

Examiner: Unassigned

Serial No.: 10/776,953

Art Unit: Unassigned

Filed: February 11, 2004

Docket: 17390 (PC25332A)

For: NOVEL TRIAZOLO-PYRIDINES
AS ANTI-INFLAMMATORY COMPOUNDS

Dated: August 12, 2004

Confirmation No.: 7596

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 3,050,525 dated August 21, 1962 to John B. Bicking;
2. Zhou L. et al., "Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine", *Clinical Immunology* 93(3):232-238 (1999);
3. International Patent Publication No. WO 01/57038 A1, published August 9, 2001; and
4. International Publication No. WO 03/044021 A2, published May 30, 2003.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.


Dated: August 12, 2004


Peter I. Bernstein

The references were cited in a Search Report dated May 7, 2004 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report. However, in accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, Applicants are not required to submit a copy of the above-cited U.S. Patent reference.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein
Registration No.: 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB:dg

IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17390 (PC25332A)

In Re Application Of: John Frederick Braganza, et al.

AUG 16 2004

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/776,953	February 11, 2004	Unassigned	23389	Unassigned	7596

Title: NOVEL TRIAZOLE-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17390 (PC25332A)

In Re Application: John Frederick Braganza, et al.

AUG 16 2004

Application No. 10/776,953	Filing Date February 11, 2004	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. 7596
-------------------------------	----------------------------------	------------------------	-----------------------	------------------------------	--------------------------

NOVEL TRIAZOLE-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____).


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I certify that this document and ~~fee~~ is being deposited on **8/12/04** th the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: August 12, 2004

Peter I. Bernstein
Registration No. 43,497
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
516-742-4343

PIB:dg

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 16 2004

Docket Number (Optional)

17390 (PC25332A)

Application Number

10/776,953

Applicant(s)

John Frederick Braganza, et al.

Filing Date

February 11, 2004

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		3,050,525	8/21/62	John B. Bicking			

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		WO 01/57038 A1	8/9/01	PCT			
		WO 03/044021 A2	5/30/03	PCT			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

		Zhou L. et al., "Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine", Clinical Immunology 93(3):232-238 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.